FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W200647351> ?p ?o ?g. }

• W200647351 endingPage "19061" @default.
• W200647351 startingPage "19061" @default.
• W200647351 abstract "19061 Background: Combination of Gemcitabine and Oxaliplatin (GEMOX) given every 3 weeks was reported to be safe and active in phase II studies in first and second line therapy of NSCLC. The aim of our trial was to assess the efficacy and safety of oxaliplatin in combination with fixed rate infusion gemcitabine in the second and third line treatment of NSCLC, and to assess quality of life (QOL). Methods: 30 patients with advanced NSCLC, with Performance status (PS) ECOG 0–1, and who had failed first or second line treatment with chemotherapy and/or tyrosine kinase inhibitors were treated with GEM 1,000 mg/m2 over 100 min in combination with O× 100 mg/m2 over 2 hours both given on days 1 and 15 of each 28-day cycle. Primary endpoint was ORR and secondary endpoints were toxicity, time to tumor progression, time to treatment failure, overall survival. QOL was assessed by the FACT-L V.4 and Lung Cancer Subscale (LCS) questionnaires. Results: From the 30 patients, 16 (53%) were males and 14 (47%) females. 20 patients were Hispanics (66%), 7 Caucasian (23%), 3 African American (10%). Median age was 56 years. PS was ECOG 0 and 1 in 14(47%) and 16(53%) respectively. Histological subtypes were adenocarcinoma in 14 patients (47%), adeno-squamos in 1(3%), squamos in 3(1%), Bronchoalveolar carcinoma in 2 (6%) and unspecified in 9 (30%) patients. The treatment was second line for 22 (73%) patients and third line for 7(23%) patients. 1 patient progressed quickly and became ineligible for the treatment after enrollment. Two patients died on study from disease progression leading to respiratory and multi-organ failure. Partial responses were achieved in 4 (13%) patients, stable disease in 12 (40%) and progressive disease in 12 (40%). Grade 3/4 adverse events were seen in <10% of the patients and included fatigue, dyspnea, anemia and multiorgan failure (1 patient). There was a 25% improvement in the QOL LCS score. Conclusion: GEMOX combination given in day 1 and 15 of every 4 weeks shows activity and tolerable side effects when used to treat patients with advanced NSCLC who have previously failed chemotherapy, tirosine kinase or angiogenesis inhibitors, with a suggestion of QOL improvement. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Lilly Oncology, sanofi-aventis sanofi-aventis" @default.
• W200647351 created "2016-06-24" @default.
• W200647351 creator A5006553031 @default.
• W200647351 creator A5007192617 @default.
• W200647351 creator A5015188727 @default.
• W200647351 creator A5053172275 @default.
• W200647351 creator A5056331208 @default.
• W200647351 creator A5083158412 @default.
• W200647351 creator A5084898582 @default.
• W200647351 creator A5088081245 @default.
• W200647351 date "2008-05-20" @default.
• W200647351 modified "2023-09-24" @default.
• W200647351 title "Gemcitabine and oxaliplatin (GEMOX), a promissing combination for the treatment of relapsed, advanced or metastatic non small cell lung cancer (NSCLC)" @default.
• W200647351 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.19061" @default.
• W200647351 hasPublicationYear "2008" @default.
• W200647351 type Work @default.
• W200647351 sameAs 200647351 @default.
• W200647351 citedByCount "1" @default.
• W200647351 crossrefType "journal-article" @default.
• W200647351 hasAuthorship W200647351A5006553031 @default.
• W200647351 hasAuthorship W200647351A5007192617 @default.
• W200647351 hasAuthorship W200647351A5015188727 @default.
• W200647351 hasAuthorship W200647351A5053172275 @default.
• W200647351 hasAuthorship W200647351A5056331208 @default.
• W200647351 hasAuthorship W200647351A5083158412 @default.
• W200647351 hasAuthorship W200647351A5084898582 @default.
• W200647351 hasAuthorship W200647351A5088081245 @default.
• W200647351 hasConcept C121608353 @default.
• W200647351 hasConcept C126322002 @default.
• W200647351 hasConcept C143998085 @default.
• W200647351 hasConcept C203092338 @default.
• W200647351 hasConcept C2776256026 @default.
• W200647351 hasConcept C2776694085 @default.
• W200647351 hasConcept C2776907518 @default.
• W200647351 hasConcept C2780258809 @default.
• W200647351 hasConcept C2780962732 @default.
• W200647351 hasConcept C31760486 @default.
• W200647351 hasConcept C526805850 @default.
• W200647351 hasConcept C535046627 @default.
• W200647351 hasConcept C71924100 @default.
• W200647351 hasConceptScore W200647351C121608353 @default.
• W200647351 hasConceptScore W200647351C126322002 @default.
• W200647351 hasConceptScore W200647351C143998085 @default.
• W200647351 hasConceptScore W200647351C203092338 @default.
• W200647351 hasConceptScore W200647351C2776256026 @default.
• W200647351 hasConceptScore W200647351C2776694085 @default.
• W200647351 hasConceptScore W200647351C2776907518 @default.
• W200647351 hasConceptScore W200647351C2780258809 @default.
• W200647351 hasConceptScore W200647351C2780962732 @default.
• W200647351 hasConceptScore W200647351C31760486 @default.
• W200647351 hasConceptScore W200647351C526805850 @default.
• W200647351 hasConceptScore W200647351C535046627 @default.
• W200647351 hasConceptScore W200647351C71924100 @default.
• W200647351 hasIssue "15_suppl" @default.
• W200647351 hasLocation W2006473511 @default.
• W200647351 hasOpenAccess W200647351 @default.
• W200647351 hasPrimaryLocation W2006473511 @default.
• W200647351 hasRelatedWork W1991358584 @default.
• W200647351 hasRelatedWork W200647351 @default.
• W200647351 hasRelatedWork W2160509211 @default.
• W200647351 hasRelatedWork W2381460883 @default.
• W200647351 hasRelatedWork W2518765238 @default.
• W200647351 hasRelatedWork W2799900329 @default.
• W200647351 hasRelatedWork W2991013230 @default.
• W200647351 hasRelatedWork W3032349186 @default.
• W200647351 hasRelatedWork W3155373832 @default.
• W200647351 hasRelatedWork W606057383 @default.
• W200647351 hasVolume "26" @default.
• W200647351 isParatext "false" @default.
• W200647351 isRetracted "false" @default.
• W200647351 magId "200647351" @default.
• W200647351 workType "article" @default.